<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219738</url>
  </required_header>
  <id_info>
    <org_study_id>20071068</org_study_id>
    <secondary_id>IRUSBUPF0002</secondary_id>
    <nct_id>NCT01219738</nct_id>
  </id_info>
  <brief_title>Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide</brief_title>
  <official_title>Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma
      membrane-mediated and do not require gene transcription and translation. One of these
      non-genomic effects is the inhibition of adrenergic agonist transport into airway vascular
      smooth muscle cells with an increase of adrenergic agonist concentrations at adrenergic
      receptor sites and enhance the physiological effects of endogenous adrenergic agonists (e.g.
      locally released norepinephrine from noradrenergic neurons) or exogenous adrenergic agonists
      (e.g. inhaled beta-adrenergic agonists).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inhaled glucocorticosteroids typically are not recommended for the treatment of acute asthma
      attacks. This practice is based on the fact that glucocorticosteroids by themselves do not
      cause rapid bronchodilation. However, the acute inhibition of adrenergic agonist disposal by
      the non-genomic action of glucocorticosteroids could lead to bronchial vasoconstriction by
      locally released norepinephrine thereby decongesting the airway wall, and potentiate the
      bronchodilator effect of a concomitantly administered beta-adrenergic agonist through the
      same mechanism. The purpose of this study is to assess the vasoconstrictive effects of single
      and repetitive high-dose budesonide inhalations in moderate to severe asthmatics who use
      inhaled glucocorticosteroids regularly. As a secondary endpoint, airway inflammation and
      airway function will also be measured with the expectation that acute improvements in airflow
      might be detectable as a result of airway decongestion, notably in subjects with moderately
      severe asthma who have lower baseline lung function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Airway Blood Flow (Qaw)</measure>
    <time_frame>participants will be followed for 6 hours after budesonide dose</time_frame>
    <description>Qaw will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>participant will be followed up to 6 hours after budesonide dose</time_frame>
    <description>FEV1 will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>budesonide 360ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>asthmatic subject received different doses of inhaled budesonide in random other</description>
  </arm_group>
  <arm_group>
    <arm_group_label>budesonide 720ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>asthmatic subject received different doses of inhaled budesonide in random other</description>
  </arm_group>
  <arm_group>
    <arm_group_label>budesonide 1440ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>asthmatic subject received different doses of inhaled budesonide in random other</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>asthmatic subject received inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide720ug 4 times</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 360ug</intervention_name>
    <description>A single inhaled dose of 360ug budesonide from a DPI.</description>
    <arm_group_label>budesonide 360ug</arm_group_label>
    <other_name>Pulmicort Flexhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 720ug</intervention_name>
    <description>A single inhaled dose of 720ug budesonide from a DPI.</description>
    <arm_group_label>budesonide 720ug</arm_group_label>
    <other_name>Pulmicort Flexhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 1440ug</intervention_name>
    <description>A single dose of 1440ug of the budesonide from DPI.</description>
    <arm_group_label>budesonide 1440ug</arm_group_label>
    <other_name>Pulmicort Flexhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide720ug 4 times</intervention_name>
    <description>720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Pulmicort Flexhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single inhaled dose of placebo from a DPI.</description>
    <arm_group_label>Budesonide720ug 4 times</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Twenty lifetime nonsmokers moderate or severe asthmatics; FEV1â‰¥50 of predicted on the
        screening day

        Exclusion Criteria:

        Women of childbearing potential who do not use accepted birth control measures; pregnant
        and breast feeding women; Cardiovascular disease and/or use of cardiovascular medication;
        Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance; Acute
        respiratory infection and or acute exacerbation of asthma within four weeks prior to the
        study; Use of systemic glucocorticosteroids within 4 weeks prior to the study; Daily ICS
        dose (fluticasone or budesonide) &gt; 500ug; Diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliana Mendes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Human Research Laboratory, University of Miami, Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Horvath G, Sutto Z, Torbati A, Conner GE, Salathe M, Wanner A. Norepinephrine transport by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003 Oct;285(4):L829-37. Epub 2003 Jun 13.</citation>
    <PMID>12807698</PMID>
  </reference>
  <reference>
    <citation>Horvath G, Lieb T, Conner GE, Salathe M, Wanner A. Steroid sensitivity of norepinephrine uptake by human bronchial arterial and rabbit aortic smooth muscle cells. Am J Respir Cell Mol Biol. 2001 Oct;25(4):500-6.</citation>
    <PMID>11694456</PMID>
  </reference>
  <reference>
    <citation>Mendes ES, Pereira A, Danta I, Duncan RC, Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J. 2003 Jun;21(6):989-93.</citation>
    <PMID>12797493</PMID>
  </reference>
  <reference>
    <citation>Brieva JL, Danta I, Wanner A. Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma. Am J Respir Crit Care Med. 2000 Jan;161(1):293-6.</citation>
    <PMID>10619834</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <results_first_submitted>November 12, 2014</results_first_submitted>
  <results_first_submitted_qc>January 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2015</results_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Eliana Mendes</investigator_full_name>
    <investigator_title>University of Miami</investigator_title>
  </responsible_party>
  <keyword>Asthma, airway blood flow, budesonide, glucocorticosteroid.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>asthmatic subject received different doses of inhaled budesonide
Budesonide: A single inhaled dose of 360ug budesonide from a DPI.
Budesonide: A single inhaled dose of 720ug budesonide from a DPI.
Budesonide: A single dose of 1440ug of the budesonide from DPI.
Budesonide: 720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
Placebo: A single inhaled dose of placebo from a DPI.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Budesonide 360</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Budesonide 720</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Budesonide 1440</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Budesonide 720- 4 Times</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Asthma</title>
          <description>asthmatic subject received different doses of inhaled budesonide
Budesonide: A single inhaled dose of 360ug budesonide from a DPI.
Budesonide: A single inhaled dose of 720ug budesonide from a DPI.
Budesonide: A single dose of 1440ug of the budesonide from DPI.
Budesonide: 720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
Placebo: A single inhaled dose of placebo from a DPI.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="22" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Airway blood flow</title>
          <units>Î¼l/min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Airway Blood Flow (Qaw)</title>
        <description>Qaw will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days.</description>
        <time_frame>participants will be followed for 6 hours after budesonide dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide 360ug</title>
            <description>Budesonide: A single inhaled dose of 360ug budesonide from a DPI.</description>
          </group>
          <group group_id="O2">
            <title>Budesonide 720ug</title>
            <description>Budesonide: A single inhaled dose of 720ug budesonide from a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Budesonide 1440ug</title>
            <description>Budesonide: A single dose of 1440ug of the budesonide from DPI.</description>
          </group>
          <group group_id="O4">
            <title>Budesonide 720ug 4 Times</title>
            <description>Budesonide: 720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo: A single inhaled dose of placebo from a DPI</description>
          </group>
        </group_list>
        <measure>
          <title>Airway Blood Flow (Qaw)</title>
          <description>Qaw will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days.</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="2.1"/>
                    <measurement group_id="O2" value="29.4" spread="2.7"/>
                    <measurement group_id="O3" value="34.1" spread="2.5"/>
                    <measurement group_id="O4" value="28.2" spread="1.9"/>
                    <measurement group_id="O5" value="5.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>FEV1 will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days.</description>
        <time_frame>participant will be followed up to 6 hours after budesonide dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide 360 ug</title>
            <description>Budesonide: A single inhaled dose of 360ug budesonide from a DPI.</description>
          </group>
          <group group_id="O2">
            <title>Budesonide 720 ug</title>
            <description>Budesonide: A single inhaled dose of 720ug budesonide from a DPI.</description>
          </group>
          <group group_id="O3">
            <title>Budesonide 1440 ug</title>
            <description>Budesonide: A single inhaled dose of 1440ug budesonide from a DPI.</description>
          </group>
          <group group_id="O4">
            <title>720ug of Budesonide 4 Times</title>
            <description>Budesonide: 720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>A single inhaled dose of placebo from a DPI</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>FEV1 will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days.</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.6"/>
                    <measurement group_id="O2" value="3.2" spread="1.9"/>
                    <measurement group_id="O3" value="1.6" spread="1.8"/>
                    <measurement group_id="O4" value="3.2" spread="2.4"/>
                    <measurement group_id="O5" value="0.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>overall study, up to six hour after each dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>Budesonide:was given in different doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eliana Mendes</name_or_title>
      <organization>University of Miami</organization>
      <phone>(305) 243-2568</phone>
      <email>e.mendes@miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

